Relay Therapeutics, Inc. Common Stock RLAY
i
Market dataready · fetched 2026-11-11T14:07:56.180Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T13:47:53.245924717Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-11T14:07:55.777553+00:00
Relay Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 15.83 | 229.9% | 26.3% | |||
| 25Δ | 16.87 | 221.3% | 22.4% | |||
| 30Δ | 17.83 | 215.3% | 19.1% | |||
| 35Δ | 18.71 | 198.6% | 15.7% | |||
| 40Δ | 19.49 | 188.4% | 13.1% | |||
| 45Δ | 20.19 | 180.6% | 11.0% | |||
| 50Δ | 20.82 | 167.9% | 9.0% | |||
| 55Δ | ||||||
| 60Δ | ||||||
| 65Δ | ||||||
| 70Δ | 22.08 | 99.7% | 2.8% | |||
| 75Δ | 22.30 | 90.5% | 2.2% | |||
| 80Δ | 17.39 | 123.2% | 2.5% | 22.51 | 81.3% | 1.6% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 15.83
- IV
- 229.9%
- B/E move
- 26.3%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 16.87
- IV
- 221.3%
- B/E move
- 22.4%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 17.83
- IV
- 215.3%
- B/E move
- 19.1%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 18.71
- IV
- 198.6%
- B/E move
- 15.7%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 19.49
- IV
- 188.4%
- B/E move
- 13.1%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 20.19
- IV
- 180.6%
- B/E move
- 11.0%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 20.82
- IV
- 167.9%
- B/E move
- 9.0%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 22.08
- IV
- 99.7%
- B/E move
- 2.8%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 22.30
- IV
- 90.5%
- B/E move
- 2.2%
80Δ
- Pseudo strike
- 17.39
- IV
- 123.2%
- B/E move
- 2.5%
- Pseudo strike
- 22.51
- IV
- 81.3%
- B/E move
- 1.6%
Options history
Table
| Date | IV (%) |
|---|---|
| 79.82% | |
| 76.88% | |
| 72.00% | |
| 75.69% | |
| 75.06% | |
| 72.41% | |
| 78.50% | |
| 83.60% | |
| 73.82% | |
| 76.50% |
Biotechnology
RLMD
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to treat central nervous system (CNS) diseases and other disorders in the…
More →RNAC
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and…
More →ROIV
Roivant Sciences Ltd (ROIV) is a transformative biopharmaceutical company focused on advancing drug development and commercialization through a distinctive business model that…
More →RPRX
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New…
More →RVMD
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is…
More →RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that decodes biology by integrating technological innovations in biology, chemistry, automation, data…
More →